Sean McSweeney
Primary Care · Norwood, MANPI 1306556899
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $288 of the $388 with a category attached, or 74.3%. Seagen Inc. accounts for 60.8% of it on its own, with 6 other manufacturers making up the rest.
Across 10 payments — averaging $38.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$236
- Amgen$47
- Daiichi Sankyo Inc.$26
- Tolmar, Inc.$25
- Genentech USA, Inc.$20
- Lilly USA, LLC$18
- plus $16 from 1 others
What the payments were for
- Food & beverage$28874%
- Education$10026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $236 |
| Amgen | 2 | $47 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TUKYSA$110
How this compares
$388 in reported general payments places this provider in the 70th percentile of 181 primary care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 21 | $379,888 |
| ImbruvicaIbrutinib | 15 | $231,496 |
| XtandiEnzalutamide | 13 | $174,811 |
| Lenalidomide | 11 | $145,463 |
| Abiraterone Acetate | 29 | $81,069 |
| EliquisApixaban | 33 | $21,183 |
| Fentanyl | 26 | $2,119 |
| Exemestane | 13 | $1,607 |
| Anastrozole | 28 | $1,016 |
| Hydroxyurea | 24 | $625 |
| Prochlorperazine Maleate | 35 | $462 |
| Acyclovir | 22 | $422 |
| Oxycodone Hcl | 34 | $360 |
| Dexamethasone | 31 | $346 |
| Pantoprazole Sodium | 15 | $310 |
Paid to pharmacies, not to this prescriber.
Other primary care in Norwood
- Christine HatchNewburyport$11K
- Kate McCabeWinchester$11K
- Alyssa FelverLee$6K
- Katherine WatermanSpringfield$6K
- Joshua AbrahamsFoxborough$6K
- Glynelle WhiteFall River$6K
- Suhaiti VillaLawrence$5K
- Dmitry PrizandBoston$5K
- Ashley KoHaverhill$4K
- Melissa BorgesDartmouth$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.